Genetic Predictors of the Development of Complications after Coronary Stenting

Taizhanova D. Kalimbetova A. Bodaubay R. Toleuova A. Toiynbekova R. Beysenbekova Z. Visternichan O. Tauesheva Z. Kadyrova I. Babenko D. Akhmaltdinova L. Kolesnichenko S. Kolesnikova Y. Avdienko O.V. Akilzhanova A. Gerotziafas G.T.
January 2023 MDPI

Journal of Personalized Medicine
2023 #13 Issue 1

Due to the fact that there are scientific discussions about the significance of gene polymorphisms in the risk of developing cardiovascular complications after a percutaneous coronary intervention, it is of interest to evaluate the genetic predictors of the development of cardiovascular events. This study is a molecular genetic study. Association with the genes of biomarkers for inflammation and immune response increases the risk of cardiovascular events: rs1234313 (TNFSF4): (A/G, OR-4.57 (2.35–8.87), p ≤ 0.0001), (A/G-A/A, OR-3.14 (1.75–5.63), p ≤ 0.0001), and (A/G, OR = 4.01 (2.19–7.36), p ≤ 0.0001); rs3184504 (SH2D3); ATXN2: (C/T, OR-2.53 (1.28–5.01), T/T, OR-2.99 (1.13–7.92), p = 0.017)), (C/T-T/T, OR-2.61 (1.35–5.07), p = 0.000), and (OR-1.89 (1.15–3.09), p = 0.009)). According to the lipid metabolism biomarker genes, rs2943634: (A/C OR-2.57 (1.18–5.62), p = 0.013); according to the endothelial biomarker genes, rs2713604: (DNAJB8-AS1; GATA2): (C/T, OR-4.27 (2.35–7.76), p ≤ 0.0001), (C/T-C/C, OR-4.13 (2.31–7.40), p ≤ 0.0001), (OR-4.05 (2.24–7.30), p ≤ 0.0001), and (C/T, OR-3.46 (1.99–6.00), p ≤ 0.0001). The regression analysis found that in the presence of the rs2943634 gene polymorphism, the risk of late cardiovascular events increases by 4.007 times with 95% CI (1.502:10.692), p = 0.006. The genes of biomarkers for the risk of cardiovascular events are rs1234313(TNFSF4), rs3184504 (SH2D3; ATXN2), rs2943634, and rs2713604 (DNAJB8-AS1; GATA2). The only predictor of the development of new cardiovascular events was rs2943634, which belongs to the group of lipid metabolism biomarkers.

complication , coronary stenting , genetic predictors , risk factors

Text of the article Перейти на текст статьи

Department of Internal Medicine Scientific and Research Center, Karaganda Medical University, Karaganda, 100000, Kazakhstan
Shared Resource Laboratory, Scientific and Research Center, Karaganda Medical University, Karaganda, 100000, Kazakhstan
National Laboratory Astana, Laboratory of Genomic and Personalized Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, Institut National de la Santé et de la Recherche Médicale, INSERM U938 and Faculté de Médecine Pierre et Marie Curie (UPMC), Sorbonne Universities, Paris, 75006, France

Department of Internal Medicine Scientific and Research Center
Shared Resource Laboratory
National Laboratory Astana
Cancer Biology and Therapeutics

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026